News – Page 877 – Endpoints News

New Sanofi CEO Hudson adds next-gen cancer drug tech to the R&D quest, buying Synthorx for $2.5B

6 years ago

Bristol-Myers is making a bee-line to the FDA with positive liso-cel data — but is it too late in the CAR-T game?

6 years ago

Patient #9 has been a concern, but Sangamo and Pfizer are bullish about winning the marathon hemophilia A gene ...

6 years ago

J&J team shows off 'breakthrough' BCMA CAR-T data, and that could cause a big headache at bluebird and Bristol-Myers

6 years ago

J&J fronts $750M cash to grab a failed cancer drug that’s been repurposed as a powerful anti-inflammatory

6 years ago

Jasper Therapeutics launches out of Stanford with new approach to stem cell treatment

6 years ago

Antibiotic developer scores $50M from biotech billionaire; Biohaven's Alzheimer's drug passes futility test

6 years ago

Ex-Celgene exec Terrie Curran puts her Phathom team in place; Caraway taps Martin Williams as CEO

6 years ago

UCB buffs up in blockbuster psoriasis race as bimekizumab beats Humira in head-to-head

6 years ago

With EMA review in progress, Novartis unveils more positive data on asthma therapy

6 years ago

Black Diamond raises another $85M to bring new oncogene approach into clinic

6 years ago

One of Wall Street’s most high-profile hedge funds pushes Alexion's CEO to the auction block — and he's not ...

6 years ago

With FDA review of its gene therapy underway, Ferring's $570M spinout delivers in PhIII bladder cancer readout

6 years ago

On the heels of a PhIII implosion, cancer biotech Mologen is turned over to the liquidator

6 years ago

While Novartis combats generic onslaught in the courts, FDA approves first Gilenya copycats

6 years ago

The future of Ipsen’s new $1.3B drug is in doubt as safety fears force the FDA to slam the brakes on late-stage ...

6 years ago

Sue Desmond-Hellmann says it's time for her to leave the Gates Foundation. Strategy chief Mark Suzman will now take ...

6 years ago

Skeptics pounce as Biogen details positive subgroup analysis on aducanumab — and both sides are digging in

6 years ago

AstraZeneca, Merck score China OK for Lynparza; Regeneron spotlights mid-stage data for rare disease drug

6 years ago

Vivek Ramaswamy’s Enzyvant is hit with a CRL for manufacturing — delaying a new therapy for an ultra-rare killer

6 years ago

Daphne Koller's AI startup ends wide search for a data chief, tapping Stanford's Serafim Batzoglou for the job

6 years ago

Novartis CEO Vas Narasimhan's R&D update spotlights next wave of drug stars as well as late-stage favorites

6 years ago

Michael Ehlers teases plan to build the next 'signature' genetic medicine company with $75M from Apple Tree Partners

6 years ago

A biotech emerges from one Deerfield's R&D donation partners

6 years ago

First page Previous page 874 875 876877878 879 880 Next page Last page